ARTICLE | Company News

Aptose Biosciences, Oregon Health & Science University, LLS cancer news

October 20, 2014 7:00 AM UTC

Aptose (formerly Lorus Therapeutics Inc.) joined the Beat AML cancer research initiative to create a profile of the possible genetic drivers of acute myelogenous leukemia (AML). Oregon's Knight Cancer Institute and Aptose will profile Aptose's APTO-253 (formerly LOR-253) against primary cells from AML patient samples collected by Beat AML. This year, Aptose plans to begin a Phase Ib trial to evaluate escalating doses of APTO-253 in adults with hematologic malignancies. The compound is a small molecule optimized to increase expression of Kruppel-like factor 4 ( KLF4; EZF). ...